Company intelligence / Profile preview
Metagen Therapeutics, Inc.
- Ownership
- Private
- Development stage
- Phase 1
Overview
Metagen Therapeutics has advanced a pipeline of gut-microbiota based therapeutics with its lead asset MGT‑001 in Phase 3 trials for ulcerative colitis. Other assets are being developed for stomach cancer and Parkinson’s disease at earlier clinical stages. The company leverages Japan's first "intestinal microbiota bank" to support nationwide implementation of FMT procedures and drug discovery efforts.
- Therapeutic areas
- GastroenterologyOncologyImmunologyNeurology
- Modalities
- Gut microbiota therapeutics (including Fecal Microbiota Transplantation/FMT)Microbiome-based drug discovery
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Metagen Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metagen Therapeutics, Inc..